Aug 2026· Journal of Clinical Investigation· Vol 136· 0 citations· 63 references
Medicine
TL;DR
It is shown that E3 ubiquitin ligase RING finger protein 10 (RNF10) protein levels were positively correlated with MASLD in both mice and humans and interfering with the expression or function of RNF10 may be a promising therapeutic strategy for MASLD.
Abstract
Metabolic dysfunction–associated steatotic liver disease (MASLD) has emerged as a global health concern. Nevertheless, its underlying pathological mechanisms remain poorly understood. Here, we showed that E3 ubiquitin ligase RING finger protein 10 (RNF10) protein levels were positively correlated with MASLD in both mice and humans. Hepatocyte-specific Rnf10 deletion attenuated liver steatosis, inflammation, and fibrosis. Conversely, adeno-associated virus–mediated hepatocyte-specific Rnf10 overexpression exacerbated MASLD-related phenotypes. Mechanistically, RNF10 interacted with carnitine palmitoyltransferase 1A and facilitated its degradation through K48-linked ubiquitination, thereby inhibiting fatty acid oxidation, promoting hepatic lipid accumulation, and ultimately exacerbating liver inflammation and fibrosis. Moreover, we utilized triantennary N-acetylgalactosamine to deliver siRNA specifically targeting Rnf10 to hepatocytes. This approach effectively ameliorated diet-induced liver steatosis, inflammation, and fibrosis in mice. Therefore, interfering with the expression or function of RNF10 may be a promising therapeutic strategy for MASLD.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease worldwide, yet approved pharmacotherapies remain limited. The ovarian tumor domain-containing protein 1 (OTUD1) has been implicated in metabolic regulation, but its role in MASLD remains unclear. OTUD1 expressio...
Mei-Qin Huang, Si-Yi Wei, Meng-Zhen-Yuan-Hua Li et al.· Molecular Biomedicine· 0 citations
BACKGROUND
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading global health burden, yet the regulatory nodes linking hepatic immune dysregulation to metabolic perturbations remain incompletely understood.
METHODS
We integrated bulk and single-cell RNA sequencing (scRNA-seq) to identify core...
Yan Wang, Shuang-Shuang Lu· Frontiers in Bioscience· 0 citations
Disordered lipid metabolism and inflammation, the hallmark features of metabolic dysfunction-associated steatohepatitis (MASH), present a significant therapeutic challenge even in the absence of obesity, making the discovery of novel pathogenic mechanisms and therapies imperative. Although Celastrol (Cel) markedly amel...
Hu Hua, Wen-Ping Zhu, Le-Hang Sun et al.· Biochimica et Biophysica Act...· 0 citations
Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive form of metabolic dysfunction-associated steatotic liver disease (MASLD) and a growing cause of chronic liver disease worldwide. Although the NLRP3 inflammasome has been implicated in MASH pathogenesis, its contribution remains controversial acros...
Daisuke Taguchi, Y. Shirakami, Toshihide Maeda et al.· Biochemistry and Biophysics...· 0 citations
Metabolic dysfunction-associated steatohepatitis (MASH) is a leading cause of liver-related morbidity and mortality. The current interventions are limited, underscoring the need for novel mechanism-based therapies. Protein tyrosine phosphatase 1B (PTP1B) regulates phosphotyrosine signaling and hepatic metabolism,...
Ming-Fo Hsu, Yoshihiro Ito, Ulrik N. Mjaaseth et al.· Molecular Medicine· 0 citations
Metabolic dysfunction-associated steatohepatitis (MASH) is rising globally despite recent therapeutic advances, highlighting the need to identify new targetable pathways. While dysregulated lipid and amino acid metabolism are established features of MASH, the interplay between these two metabolic pathways remains unexp...
S. Anand, Sandeep Das, Fabio Arias et al.· Journal of Clinical Investig...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.